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Summary Diseases of the bone are becoming increasingly prevalent. Persons with
epilepsy treated with antiepileptic drugs (AEDs) are at greater risk as evidenced by
changes in bone turnover, osteoporosis, alterations in bone quality, and fracture.
Biochemical indices of bone and mineral metabolism including calcium, vitamin D,
parathyroid hormone, and bone turnover markers can be affected. AED exposure is a
causeofsecondaryosteoporosiswithdecreasedbonemineraldensity (BMD)secondary to
poor bone accrual in children or accelerated bone loss in adults. Early reports described
osteomalacia, a change in bone quality with increased unmineralized bone. Recent
studiesdonotrevealosteomalacia,buttheremaybemoresubtlechanges inbonequality.
Multiple studies have foundan increased riskof fractures inassociationwithepilepsyand
AED exposure. Cytochrome P450 enzyme inducing AEDs are most commonly associated
with a negative impact on bone, but studies also suggest an effect of valproate. There is
limited data regarding the newer AEDs. No single mechanism has emerged to explain all
the changes in bone in association with epilepsy and AEDs. Although multiple therapies
are available for the treatment of bone disease, there is limited study in persons with
epilepsy. It is recommended that all persons obtain adequate amounts of calcium and
vitamin D. In addition BMD screening is warranted for persons with long-term AED
exposure particularly if they have other risk factors for bone disease.
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182 A. PackIntroduction
Diseases of the bone and joint have been gaining
recognition, particularly as the population ages. In
the United States, approximately 50% of women and
25% of men will suffer from a fracture.1 The costs of
these fractures are tremendous including loss of
daily functioning and jobs, visits to doctor’s offices
and emergency rooms, hospitalizations, and admis-
sions to nursing homes. TheWHO has recognized this
growing concern and developed an international
initiative to expand awareness and research in this
field. Internationally, the years 2000—2010 are the
decade of the bone and joint.
Studies suggest that persons with epilepsy trea-
ted with antiepileptic drugs (AEDs) may be at an
increased risk for bone disease including changes in
bone turnover, osteoporosis, alterations in bone
quality, and most importantly fracture. Although
bone disease is traditionally thought of as a disease
in women, the changes associated with epilepsy and
AEDs are not gender specific and include both men
and women. Unfortunately, despite growing evi-
dence associating epilepsy and AEDs in particular
with bone disease, there remains no consensus on
whom and when to screen as well as whom and how
to treat. This review will highlight current evidence
associating epilepsy and AEDs with diseases of the
bone.Biochemical indices of bone and
mineral metabolism and bone turnover
Bone structure is composed primarily of calcium and
phosphate. Calcium has three definable fractions
and the ionized fraction is tightly maintained. The
active metabolites of vitamin D function as a reg-
ulator of calcium concentration by increasing effi-
ciency of intestinal calcium absorption. In addition,
vitamin D recruits stem cells in bone to become
mature osteoclasts. Some studies describe reduced
calcium concentrations in association with AED
treatment,2 whereas others do not find significant
overall reductions in calcium concentrations.3
There may however, be a differential AED effect
with some AEDs significantly reducing calcium rela-
tive to others.4 Similarly some, especially early
studies, reported low vitamin D concentrations in
association with enzyme inducing AEDs,2 but more
recent studies in ambulatory persons do not con-
sistently find reduced vitamin D metabolites.4,5
Calcium and its ionized fraction are regulated by
parathyroid hormone (PTH). In response to
decreased concentrations of calcium, PTH secretion
is increased and the concentration of calcium isincreased by increasing the uptake of calcium in
the distal renal tubules, improving calcium intest-
inal efficiency, and finally by increasing bone resorp-
tion thereby mobilizing calcium stores in bone. PTH
is elevated in some2 but not all5,6 studies of persons
with epilepsy treated with AEDs.
Bone turnover including osteoblastic (bone for-
mation) and osteoclastic (bone resorption) func-
tions can be assessed by either serologic or urine
measurements. Bone formation markers include
osteocalcin and bone-specific alkaline phosphatase.
Bone resorption markers are measurements of col-
lagen breakdown products in the serum and urine.
Elevations of these markers have been reported as
being elevated in association with AED treat-
ment.4,5,7 This elevation suggests a pattern of
increased turnover which may result in bone loss
over time.Bone mineral density (BMD)
The life cycle of bone is characterized by several
distinct phases. In childhood and adolescence bone
is accrued, most significantly in adolescence. Peak
BMD is then obtained between ages 20 and 30. In the
ensuing years, there is typically a gradual loss of
bone. Some time periods are associated with an
increased susceptibility to bone loss, for instance
in the perimenopausal years.
BMD accumulation and maintenance occur as a
function of the coupling of bone resorption and
formation. Osteoclasts are the cells responsible
for bone resorption whereas osteoblasts are the
cells that form bone. An uncoupling of these func-
tions results in either low turnover or high turnover.
In childhood these pathologic processes affect bone
accumulation, whereas bone loss occurs in the adult
years. Osteopenia and osteoporosis are gradations
of the same pathology with osteoporosis being more
severe. Primary osteoporosis is defined as bone loss
in the perimenopausal years and in older men and
women. Secondary osteoporosis occurs in associa-
tion with medical illnesses or medications that
results in bone loss (Table 1). AED exposure can
result in secondary bone loss. Studies in children
find lower BMD when compared to matched controls
suggesting poor bone accrual.8 In adults low BMD has
been described in institutionalized and ambulatory
populations at multiple sites including the total hip,
femoral neck, and lumbar spine.9 Unfortunately,
most studies are cross-sectional and often lack con-
trols, limiting interpretation. One study controlled
for genetics by using a sibling/twin pair cohort.10
The subjects were discordant for treatment with
AEDs. BMD analysis revealed significant reduction in
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Table 1 Secondary causes of osteoporosis
Gastrointestinal malabsorption
Vitamin D and/or calcium deficiency
Hyperthyroidism
Hyperparathyroidism
Cushing’s syndrome
Rheumatoid arthritis and other inflammatory
conditions
Alcoholism
Renal disease
Liver disease
Osteogenesis imperfecta
Marfan’s syndrome
Homocystinuria
Medications
Glucocorticosteroids
Immunosuppressants (cyclosporine)
Antiepileptic drugs
GnRH agonists
Heparin
Cancer chemotherapy
Depot medroxyprogesterone acetate
Excess thyroid hormone
Diuretics
Metoclopramide
Methotrexate
Antiretroviral therapy for HIVBMD in those siblings treated with AEDs, with the
most significant differences being among those trea-
ted with AEDs for greater than 2 years, persons
treated with enzyme inducing AEDs, and those older
than age 40. Some prospective studies in men and
women do find significant bone loss in persons with
epilepsy treated with AEDs when compared to con-
trols. For instance a study of men3 found significant
annual BMD loss occurring in young men (24—44) at
the femoral neck of the hip, not typically an age
group thought to be at risk for bone loss; and in a
cohort of postmenopausal women, significant loss
occurred in continuous AED users when compared to
non-users.11Bone quality
Bone strength is characterized by both bone density
and bone quality. Bone quality describes multiple
features of bone including structural and material
properties as well as biochemical strength. Inter-
estingly, a meta-analysis of both studies of fracture
and BMD found that the reported increased fracture
risk could not be explained by BMD reports in per-
sons with epilepsy treated with AEDs.12 Perhaps
then changes in bone quality also increase the risk
of bone disease and fracture. Osteomalacia is a
marked change in bone quality whereby pathologicspecimens reveal increased osteoid or unminera-
lized bone secondary to reduced calcium and/or
vitamin D. Osteomalacia and rickets (involving
growth plate in children) associated with AED treat-
ment were noted in early studies. Review of these
studies finds that most patients were institutiona-
lized and therefore, other confounding variables
such as poor diet likely influenced the findings.
Biopsy studies in ambulatory persons do not reveal
osteomalacia.2 There may however be more subtle
changes in bone quality. Interestingly, bone speci-
mens in rats treated with levetiracetam, phenytoin,
and valproate had evidence of changes in bone
quality.13 Biochemical competence was affected
in those rats treated with low dose levetiracetam.
Further study needs to be done to more definitively
assess bone quality in association with epilepsy and
AED treatment.Fracture
Fractures occur as a result of multiple factors
including low bone mineral density or osteoporosis,
altered bone quality, or a propensity to fall. As
already discussed, AED exposure increases one’s risk
of osteoporosis and may impact bone quality. In
addition, persons with epilepsy have an increased
risk of falling secondary to either seizures or side
effects of AEDs such as poor coordination. Multiple
studies have found a 2- to 6-fold increased risk of
fractures in persons with epilepsy treated with
antiepileptic drugs.14 A meta-analysis of fracture
studies identified AED exposure as a high risk factor
with a relative risk or odds ratio (OR) of greater than
or equal to 2.0.15 However, many of these studies
are small and poorly controlled. Interestingly, a
recent large population-based-controlled registry
study found an elevated risk at all sites after con-
trolling for age and sex.16 The hip was identified as
having the highest risk (OR 2.79; 95% CI 2.41—3.24).
Using the same database and a nested case con-
trol study design, long-term AED use was associated
with an increased risk of fracture, particularly in
women.17AEDs
Cytochrome P450 enzyme inducing AEDs are most
commonly associated with a negative impact on
bone.9 Although carbamazepine is an enzyme indu-
cing AED, data is more conflicting. Some studies find
changes in bone density and turnover whereas
others do not. One study suggests a change in bone
turnover markers5,6 in children treated with carba-
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Table 2 Possible mechanisms of AED related bone
disease
Hepatic induction of cytochrome P450 enzymes leadingmazepine. Prior to initiation of carbamazepine
treatment, adolescents had an evaluation of cal-
cium, vitamin D metabolites, PTH, and bone turn-
over markers and were compared to age, sex, and
pubertal matched controls. Significant changes in
turnover markers and not PTH or vitamin D meta-
bolites were found after 1 and 2 years after treat-
ment suggesting that these adolescents may have
long-term effects on bone density secondary to
elevated turnover. Similarly a 6-month longitudinal
study found significant BMD reductions in persons
treated with carbamazepine.18 Oxcarbazepine at
higher doses is also an enzyme inducer. Interestingly
adults treated with this AED had reduced vitamin D
metabolites and elevated PTH that was most sig-
nificant at higher doses.19
Although valproate is a cytochrome P450 enzyme
inhibitor, studies do suggest an effect on bone.7,18,20
BMD has been found to be reduced in both children
and adults at multiple sites. In addition, bone turn-
over markers may be elevated.
Data regarding lamotrigine’s effects on bone are
mixed. Children treated with lamotrigine had
shorter stature when compared to matched con-
trols.21 The investigators speculated that this
finding was explained by significantly reduced exer-
cise. Another prospective study found elevated
osteocalcin, a marker of bone formation, in asso-
ciation with lamotrigine treatment.18 In contrast,
premenopausal women treated with lamotrigine
did not have significant reductions in BMD or
changes in bone turnover markers.4
Topiramate and zonisamide’s effects on bone
have received limited study. As both are carbonic
anhydrase inhibitors resulting in renal acidosis there
may be secondary abnormalities on bone. Interest-
ingly though, carbonic anhydrase potentiates the
action of osteoclasts and therefore, inhibitors may
have a bone sparing effect. This hypothesis is sup-
ported by findings in women with glaucoma treated
with acetazolomide, another carbonic anhydrase
inhibitor.22 A double blind randomized preliminary
study of topiramate as treatment for obesity did not
find significant changes in bone turnover markers
compared to placebo controls.23
Limited data also exists on levetiracetam’s
effects on bone. A preliminary study of a limited
sample size finds no effects.24to increased metabolism of vitamin D
Direct action of AEDs on osteoblasts
Impaired calcium absorption
Elevated homocysteine
Inhibition of response to PTH
Hyperparathyroidism
Reduced reproductive sex hormones
Reduced vitamin KMechanisms
As most evidence associates cytochrome P450
enzyme inducing AEDs with abnormalities in bone,
the induction of these enzymes has been proposed
as being themainmechanism to describe this effect.This induction potentially increases catabolism of
vitamin D to inactive metabolites resulting in reduc-
tion of calcium, a subsequent elevation in PTH, and
elevation in bone turnover. These clinical findings
are supported by recent basic studies evaluating the
effect of these AEDs on the expression of specific
cytochrome P450 isoenzymes involved in vitamin D
metabolism. Phenobarbital, phenytoin, and carba-
mazepine are among a class of drugs known as
xenobiotics. Xenobiotics activate a nuclear receptor
known as either the steroid and xenobiotic receptor
(SXR) or pregnane X receptor (PXR). One study found
that xenobiotics upregulate 25-hydroxyvitamin D3-
24-hydroxylase (CYP24) in the kidney through acti-
vation of PXR. This enzyme catalyzes the conversion
of 25-hydroxyvitamin D to its inactive metabolite,
24,25-dihyroxyvitamin, rather than to its active
metabolite, 1,25-dihyroxyvitamin D.25 Other inves-
tigators found that xenobiotic activation of PXR did
not upregulate CYP24 but did increase expression of
a different isoenzyme, CYP3A4, in the liver and
small intestine.26 This enzyme converts vitamin D
to more polar inactive metabolites. Despite some of
the clinical and basic studies’ findings, the biochem-
ical findings supporting this mechanism are not
consistently found in ambulatory persons. In addi-
tion, valproate, an enzyme inhibitor may also nega-
tively impact bone. Animal studies suggest other
potential mechanisms including effects on bone
quality and reduced calcium absorption.13,27 Other
potential mechanisms may also explain described
abnormalities in bone (Table 2).28,29 Further animal
and clinical studies are needed to elucidate poten-
tial mechanisms associating AEDs with abnormalities
in bone.Screening
No official clear recommendations for screening
bone health in persons with epilepsy treated with
AEDs are available. Currently the most sensitive
predictor of fracture is BMD and therefore, it is
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ments in person at risk. Multiple risk factors increase
one’s risk of osteoporosis and fracture (Table 1). In
addition to the secondary causes of osteoporosis
listed in Table 1, a family history of osteoporosis,
Caucasian or Asian races, tobacco use, and small
body frame increase one’s risk of osteoporosis.
Importantly, the more risk factors that are present
the higher one’s risk of fracture especially if BMD is
low.30 If a person has prolonged exposure to AEDs,
particularly with those AEDs commonly associated
with abnormalities in bone (enzyme inducing AEDs
and valproate), BMD screening as assessed by dual
energy X-ray absorptiometry should be performed.
There is no defined role for obtaining bone turnover
markers although they may be useful if available.Treatment
Multiple therapies are available for the treatment of
bone disease (Table 3). Some are recommended in
specific clinical situations. For instance hormone
replacement therapy may be useful in a menopausal
woman with other significant symptoms including
hot flashes. However, if the woman has epilepsy she
may be at risk for an increased seizure activity.31
Bisphosphonates are known to increase BMD and
reduce the risk of fracture but are not routinely
recommended in premenopausal women particu-
larly as the teratogenic potential is unknown. Lim-
ited study is available on these treatments in
persons with epilepsy treated with AEDs. A recent
randomized double blind trial over 1 year compared
low dose (400 IU/day for adults and children) and
high dose (4000 IU/day for adults and 2000 IU/day
for children) vitamin D supplementation.32 In the
adults, the baseline BMD was reduced at all sites
when compared to age and gender matched con-
trols. After 1 year, there were significant increases
in BMD at all sites in those receiving high dose butTable 3 Available treatments for osteoporosis
Calcium and vitamin D supplementation
Bisphosphonates
Alendronate sodium
Alendronate sodium plus 2800 IU vitamin D3
Ibandronate sodium
Risedronate sodium
Risedronate sodium plus 500 mg calcium carbonate
Hormone therapy
Selective estrogen receptor modulators
Raloxifene
Parathyroid hormonenot low dose vitamin D. The children had normal
BMD when compared to age and gender matched
controls and had significant and comparable
increases in BMD in both treatment groups. This
study suggests that persons with epilepsy treated
with AEDs, should be counseled about adequate
vitamin D intake. For those taking enzyme inducing
AEDs, higher doses of vitamin D than currently
recommended are suggested. In addition, adequate
calcium intake and supplementation if necessary
are advised.Recommendations
Epilepsy and in particular AEDs are associated with
adverse affects on bone including elevated bone
turnover, reduced BMD, potential changes in bone
quality, and fracture. The increased fracture risk
may be a result of multiple factors including the
discussed adverse effects in bone as well as an
increased propensity to fall secondary to the sei-
zures themselves or side effects of medications (e.g.
poor coordination). Enzyme inducing AEDs and
valproate in multiple studies results in these bone
abnormalities. There is limited data regarding the
newer AEDs. It is recommended that all persons
obtain adequate amounts of calcium and vitamin
D. In addition BMD screening is warranted for per-
sons with long-term AED exposure particularly if
they have other risk factors for bone disease.References
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